Cell Therapeutics to submit supplemental filing for Zevalin

09/22/2008 | MarketWatch

Cell Therapeutics is planning to submit later this year a supplemental Biologics License Application that proposes a label expansion for the use of Zevalin as consolidation therapy after remission induction in previously untreated patients with follicular non-Hodgkin's lymphoma. The company, following a meeting with the FDA, said the First-Line Indolent Trial results of Zevalin are sufficient to support the sBLA.

View Full Article in:

MarketWatch

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Market Intelligence Manager
Olympus Corporation of the Americas
Southborough, MA
Director, Compliance - Health Plan Privacy & Security
Kaiser Permanente
Oakland, CA
Regulatory Counsel
Food and Drug Administration
Silver Spring, MD
Pharmacy Care Manager
National Association of Chain Drug Stores
Arlington, VA
Vice President, Commercial Markets
Meridian Health
Neptune, NJ